← All trials
NCT05570409
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 3, 2022
- Primary completion
- Nov 3, 2026
- Completion date
- Apr 3, 2027
- First posted
- Oct 6, 2022
- Last posted
- Oct 6, 2022
- Enrollment
- 130
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ludwig Maximilians UniversityLead sponsor
- University of Duisburg-EssenCollaborator
- Ludwig Maximilians UniversityOverall official - principal investigator
- Ludwig Maximilians UniversityReponsible party - principal investigator
- University of Erlangen-NurembergCollaborator
- Humboldt UniversityCollaborator
- Technical University of MunichCollaborator
- University of TuebingenCollaborator
- German Center for Cardiovascular Research e. V. (DZHK)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.